Addex Therapeutics’ (ADXN) Buy Rating Reaffirmed at HC Wainwright

Addex Therapeutics (NASDAQ:ADXN)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report released on Wednesday, Benzinga reports. They currently have a $30.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 219.15% from the stock’s current price.

Addex Therapeutics Stock Up 1.3 %

Shares of Addex Therapeutics stock opened at $9.40 on Wednesday. The stock’s 50-day simple moving average is $9.14 and its 200-day simple moving average is $10.58. Addex Therapeutics has a 52 week low of $5.00 and a 52 week high of $27.90. The company has a market capitalization of $9.96 million, a price-to-earnings ratio of -0.54 and a beta of 1.79.

Addex Therapeutics (NASDAQ:ADXN) last issued its earnings results on Monday, September 30th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($1.70). Addex Therapeutics had a negative return on equity of 364.24% and a negative net margin of 818.50%. The firm had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.26 million. On average, equities analysts expect that Addex Therapeutics will post -0.36 earnings per share for the current year.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.